251 related articles for article (PubMed ID: 17267661)
1. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
Lyu MA; Cheung LH; Hittelman WN; Marks JW; Aguiar RC; Rosenblum MG
Mol Cancer Ther; 2007 Feb; 6(2):460-70. PubMed ID: 17267661
[TBL] [Abstract][Full Text] [Related]
2. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells.
Nimmanapalli R; Lyu MA; Du M; Keating MJ; Rosenblum MG; Gandhi V
Blood; 2007 Mar; 109(6):2557-64. PubMed ID: 17119117
[TBL] [Abstract][Full Text] [Related]
3. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
Lyu MA; Rai D; Ahn KS; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Gandhi V; Rosenblum MG
Neoplasia; 2010 May; 12(5):366-75. PubMed ID: 20454508
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
Lyu MA; Pham LV; Sung B; Tamayo AT; Ahn KS; Hittelman WN; Cheung LH; Marks JW; Cho MJ; Ford RJ; Aggarwal BB; Rosenblum MG
Biochem Pharmacol; 2012 Aug; 84(4):451-8. PubMed ID: 22687624
[TBL] [Abstract][Full Text] [Related]
5. Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.
Luster TA; Mukherjee I; Carrell JA; Cho YH; Gill J; Kelly L; Garcia A; Ward C; Oh L; Ullrich SJ; Migone TS; Humphreys R
PLoS One; 2012; 7(10):e47361. PubMed ID: 23056634
[TBL] [Abstract][Full Text] [Related]
6. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF.
Abu-Rish EY; Amrani Y; Browning MJ
Rheumatology (Oxford); 2013 Jul; 52(7):1190-201. PubMed ID: 23436580
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
Parameswaran R; Yu M; Lyu MA; Lim M; Rosenblum MG; Groffen J; Heisterkamp N
Leukemia; 2012 Aug; 26(8):1786-96. PubMed ID: 22373785
[TBL] [Abstract][Full Text] [Related]
9. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation.
Hondowicz BD; Alexander ST; Quinn WJ; Pagán AJ; Metzgar MH; Cancro MP; Erikson J
Int Immunol; 2007 Apr; 19(4):465-75. PubMed ID: 17369193
[TBL] [Abstract][Full Text] [Related]
10. B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosus.
Spinelli FR; Barbati C; Cecarelli F; Morello F; Colasanti T; Vomero M; Massaro L; Orefice V; Alessandri C; Valesini G; Conti F
Arthritis Res Ther; 2019 Nov; 21(1):245. PubMed ID: 31752963
[TBL] [Abstract][Full Text] [Related]
11. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.
Jacob CO; Yu N; Guo S; Jacob N; Quinn WJ; Sindhava V; Cancro MP; Goilav B; Putterman C; Migone TS; Stohl W
Arthritis Rheum; 2013 Apr; 65(4):1043-54. PubMed ID: 23334904
[TBL] [Abstract][Full Text] [Related]
12. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.
Nelke J; Medler J; Weisenberger D; Beilhack A; Wajant H
MAbs; 2020; 12(1):1807721. PubMed ID: 32840410
[TBL] [Abstract][Full Text] [Related]
13. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
[TBL] [Abstract][Full Text] [Related]
14. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
Wong DP; Roy NK; Zhang K; Anukanth A; Asthana A; Shirkey-Son NJ; Dunmire S; Jones BJ; Lahr WS; Webber BR; Moriarity BS; Caimi P; Parameswaran R
Nat Commun; 2022 Jan; 13(1):217. PubMed ID: 35017485
[TBL] [Abstract][Full Text] [Related]
15. Stoichiometry of Heteromeric BAFF and APRIL Cytokines Dictates Their Receptor Binding and Signaling Properties.
Schuepbach-Mallepell S; Das D; Willen L; Vigolo M; Tardivel A; Lebon L; Kowalczyk-Quintas C; Nys J; Smulski C; Zheng TS; Maskos K; Lammens A; Jiang X; Hess H; Tan SL; Schneider P
J Biol Chem; 2015 Jun; 290(26):16330-42. PubMed ID: 25953898
[TBL] [Abstract][Full Text] [Related]
16. Expression and effects of B-lymphocyte stimulator and its receptors in T cell-mediated autoimmune arthritis.
Chang Y; Sun X; Jia X; Xu S; Wei F; Yang X; Wei W
Int Immunopharmacol; 2015 Feb; 24(2):451-457. PubMed ID: 25598291
[TBL] [Abstract][Full Text] [Related]
17. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.
Wen X; Lyu MA; Zhang R; Lu W; Huang Q; Liang D; Rosenblum MG; Li C
Mol Imaging Biol; 2011 Aug; 13(4):721-9. PubMed ID: 20686856
[TBL] [Abstract][Full Text] [Related]
19. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
[TBL] [Abstract][Full Text] [Related]
20. Investigating the Role of BAFF and Its Receptors in Renal Transplant Recipients with Chronic Antibody-Mediated Rejection.
Afzali S; Salehi S; Shahi A; Esmaeili M; Farashi Bonab S; Peykari A; Bagherpour F; Ansaripour B; Soleimanian T; Pour-Reza-Gholi F; Amirzargar A
J Immunol Res; 2021; 2021():6654992. PubMed ID: 33748289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
